AbbVie Inc. (NYSE:ABBV) Upgraded by Zacks Investment Research to "Buy"


AbbVie Inc. (NYSE:ABBV) Upgraded by Zacks Investment Research to

The stock now has Weekly Volatility of 3.63% and Monthly Volatility of 2.41%.

ABBV reported mixed results in the third quarter of 2017. (The) restated a buy rating and issued a $100.00 target price (up from $85.00) on shares of AbbVie in a research note on Friday, September 8th. Vetr lowered shares of AbbVie from a "strong-buy" rating to a "buy" rating and set a $67.75 price objective for the a report on Wednesday, June 29th. Zacks Investment Research raised AbbVie from a sell rating to a hold rating in a research report on Thursday, July 13th. Eight equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock.

AbbVie (ABBV) opened at 89.56 on Tuesday. MEIP's latest closing price was 34.52% away from the average price of 200 days while it maintained a distance of 8.45% from the 50 Day Moving Average and 11.52% away compared to its SMA 20. Trading volume for AbbVie Inc. was 10.27 Million in its previous trading session. (ABBV) on Friday reported third-quarter profit of $1.63 billion. The company reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.02.

Oct 27 (Reuters) - AbbVie Inc forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago, driving the USA drugmaker's shares up 4 percent on Friday. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. AbbVie's revenue was up 7.6% on a year-over-year basis.

"In a very choppy earnings season, have to hand it to AbbVie for delivering", Evercore ISI analyst Joshua Schimmer said.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and global copyright laws. Finally, San Francisco Sentry Investment Group CA purchased a new stake in AbbVie during the 2nd quarter valued at about $193,000.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Moreover, Lodestar Invest Counsel Ltd Liability Company Il has 0.22% invested in AbbVie Inc (NYSE:ABBV) for 23,731 shares. Garland Mngmt Inc reported 2.96% of its portfolio in AbbVie Inc (NYSE:ABBV). The ex-dividend date is Wednesday, October 12th. AbbVie's payout ratio is now 62.90%.

In the year so far, AbbVie's shares have surged 48.6%, significantly outperforming the industry 's 16.1% rally. The insider ALBAN CARLOS sold 43,000 shares worth $2.88 million. The Company's services and solutions are created to assist land owners with monetizing undervalued assets by bringing commodities, such as gold, silver, gas and oil, and dolomite to market. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The stock was sold at an average price of $65.00, for a total transaction of $3,250,000.00. The company now has an average rating of "Buy" and a consensus price target of $70.64.

Other institutional investors also recently bought and sold shares of the company. The disclosure for this sale can be found here. Franklin Parlapiano Turner & Welch LLC acquired a new stake in shares of AbbVie in the first quarter valued at about $108,000. DORCHESTER WEALTH MANAGEMENT Co increased its position in AbbVie by 2.5% in the 1st quarter. Following the completion of the sale, the insider now owns 96,074 shares in the company, valued at $6,733,826.66. ProShare Advisors LLC increased its position in AbbVie by 7.1% in the 1st quarter.

Texas Permanent School Fund increased Spdr S&P Midcap 400 Etf Tr (MDY) stake by 1,600 shares to 3,600 valued at $1.14M in 2017Q2. Martingale Asset Management LP sold 58,206 shares as the company's stock declined 16.73% while stock markets rallied. Finally, RNC Capital Management LLC raised its stake in AbbVie by 1.2% in the second quarter.

Geode Capital Management Llc, which manages about $254.31B US Long portfolio, upped its stake in Flowserve Corp (NYSE:FLS) by 59,164 shares to 1.37M shares, valued at $63.55M in 2017Q2, according to the filing.



© 2015 Leader Call. All Rights reserved.